Related Experiment Video
Updated: Aug 14, 2025

Author Spotlight: An Integrated Workflow to Study the Promoter-Centric Spatio-Temporal Genome Architecture in Scarce Cell Populations
Published on: April 21, 2023
Dr.Nod: computational framework for discovery of regulatory non-coding drivers in tissue-matched distal regulatory
Marketa Tomkova1,2,3, Jakub Tomek4, Julie Chow1
1Department of Biochemistry and Molecular Medicine, University of California, Davis, CA 95616, USA.
Abstract:
The discovery of cancer driver mutations is a fundamental goal in cancer research. While many cancer driver mutations have been discovered in the protein-coding genome, research into potential cancer drivers in the non-coding regions showed limited success so far. Here, we present a novel comprehensive framework Dr.Nod for detection of non-coding cis-regulatory candidate driver mutations that are associated with dysregulated gene expression using tissue-matched enhancer-gene annotations. Applying the framework to data from over 1500 tumours across eight tissues revealed a 4.4-fold enrichment of candidate driver mutations in regulatory regions of known cancer driver genes. An overarching conclusion that emerges is that the non-coding driver mutations contribute to cancer by significantly altering transcription factor binding sites, leading to upregulation of tissue-matched oncogenes and down-regulation of tumour-suppressor genes. Interestingly, more than half of the detected cancer-promoting non-coding regulatory driver mutations are over 20 kb distant from the cancer-associated genes they regulate. Our results show the importance of tissue-matched enhancer-gene maps, functional impact of mutations, and complex background mutagenesis model for the prediction of non-coding regulatory drivers. In conclusion, our study demonstrates that non-coding mutations in enhancers play a previously underappreciated role in cancer and dysregulation of clinically relevant target genes.
Insights
Non-coding mutations in enhancers drive cancer by altering gene expression. Our novel framework, Dr.Nod, identifies these crucial cancer driver mutations, revealing their significant role in oncogenesis.
Area of Science:
- Genomics
- Cancer Research
- Molecular Biology
Background:
- Cancer driver mutations are key to understanding cancer.
- Most known drivers are in protein-coding regions, with limited success in non-coding regions.
- Non-coding regions, particularly enhancers, are under-explored for cancer drivers.
Purpose of the Study:
- To develop a comprehensive framework, Dr.Nod, for detecting non-coding cis-regulatory candidate driver mutations.
- To associate these mutations with dysregulated gene expression using tissue-matched enhancer-gene annotations.
- To investigate the role of non-coding mutations in cancer development.
Main Methods:
- Developed the Dr.Nod framework for non-coding driver mutation detection.
- Utilized tissue-matched enhancer-gene annotations.
- Applied the framework to over 1500 tumors across eight tissues.
Main Results:
- Identified a 4.4-fold enrichment of candidate driver mutations in regulatory regions of known cancer genes.
- Demonstrated that non-coding mutations alter transcription factor binding sites, affecting oncogene and tumor suppressor gene expression.
- Found that over half of detected mutations are >20 kb from the genes they regulate.
Conclusions:
- Non-coding enhancer mutations play a significant, previously underappreciated role in cancer.
- Dr.Nod framework highlights the importance of tissue-matched maps and functional mutation impact.
- These findings advance the prediction of non-coding regulatory drivers and understanding of cancer genetics.
Related Concept Videos
Cis-regulatory Sequences
Combinatorial Gene Control
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
Cooperative Binding of Transcription Regulators
Regulation of Expression at Multiple Steps

